My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 107

    1.

    Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis.

    Xie F, Blackhouse G, Assasi N, Gaebel K, Robertson D, Goeree R.

    Cost Eff Resour Alloc. 2009 Dec 11;7:20.PMID: 20003364 [PubMed]Free PMC ArticleFree textRelated citations

    2.

    Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.

    Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM.

    Pharmacoeconomics. 2009;27(7):609-21. doi: 10.2165/11312710-000000000-00000.PMID: 19663531 [PubMed - indexed for MEDLINE]Related citations

    3.

    A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

    Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

    Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.PMID: 17049139 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    4.

    Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

    McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

    Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.PMID: 17651658 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    5.

    Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

    Shepherd J, Jones J, Takeda A, Davidson P, Price A.

    Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183. Review.PMID: 16904047 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    6.

    A review of infliximab use in ulcerative colitis.

    Wilhelm SM, McKenney KA, Rivait KN, Kale-Pradhan PB.

    Clin Ther. 2008 Feb;30(2):223-30. Review.PMID: 18343261 [PubMed - indexed for MEDLINE]Related citations

    7.

    A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis.

    Tsai HH, Punekar YS, Morris J, Fortun P.

    Aliment Pharmacol Ther. 2008 Nov 15;28(10):1230-9. Epub 2008 Aug 24.PMID: 18729845 [PubMed - indexed for MEDLINE]Related citations

    8.

    The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.

    Fox M, Mealing S, Anderson R, Dean J, Stein K, Price A, Taylor RS.

    Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. Review.PMID: 17999842 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    9.

    Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis.

    Boonen A, van der Heijde D, Severens JL, Boendermaker A, Landewé R, Braun J, Brandt J, Sieper J, van der Linden S.

    Ann Rheum Dis. 2006 Feb;65(2):201-8. Epub 2005 Jul 13.PMID: 16014677 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

    10.

    Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry.

    Brennan A, Bansback N, Nixon R, Madan J, Harrison M, Watson K, Symmons D.

    Rheumatology (Oxford). 2007 Aug;46(8):1345-54. Epub 2007 Jun 11.PMID: 17562686 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    11.

    Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.

    Punekar YS, Hawkins N.

    Eur J Health Econ. 2010 Feb;11(1):67-76. Epub 2009 Oct 21.PMID: 19844750 [PubMed - in process]Related citations

    12.

    The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.

    Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, Somerville M, Price A, Stein K.

    Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. Review.PMID: 17999840 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    13.

    Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

    Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

    Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.PMID: 16948890 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    14.

    The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.

    Bravo Vergel Y, Hawkins NS, Claxton K, Asseburg C, Palmer S, Woolacott N, Bruce IN, Sculpher MJ.

    Rheumatology (Oxford). 2007 Nov;46(11):1729-35.PMID: 17956918 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    15.

    Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.

    Xie F, Blackhouse G, Assasi N, Campbell K, Levin M, Bowen J, Tarride JE, Pi D, Goeree R.

    Clin Ther. 2009 May;31(5):1082-91; discussion 1066-8.PMID: 19539109 [PubMed - indexed for MEDLINE]Related citations

    16.

    An economic evaluation of rizatriptan in the treatment of migraine.

    Thompson M, Gawel M, Desjardins B, Ferko N, Grima D.

    Pharmacoeconomics. 2005;23(8):837-50.PMID: 16097844 [PubMed - indexed for MEDLINE]Related citations

    17.

    Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis.

    Lyseng-Williamson KA, Foster RH.

    Pharmacoeconomics. 2004;22(2):107-32. Review.PMID: 14731052 [PubMed - indexed for MEDLINE]Related citations

    18.

    Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden.

    Bansback NJ, Brennan A, Ghatnekar O.

    Ann Rheum Dis. 2005 Jul;64(7):995-1002. Epub 2004 Nov 18.PMID: 15550533 [PubMed - indexed for MEDLINE]Free PMC ArticleFree textRelated citations

    19.

    Adalimumab for the treatment of psoriasis.

    Turner D, Picot J, Cooper K, Loveman E.

    Health Technol Assess. 2009 Sep;13 Suppl 2:49-54. Review.PMID: 19804689 [PubMed - indexed for MEDLINE]Free ArticleRelated citations

    20.

    Economic evaluation of systemic therapies for moderate to severe psoriasis.

    Sizto S, Bansback N, Feldman SR, Willian MK, Anis AH.

    Br J Dermatol. 2009 Jun;160(6):1264-72. Epub 2008 Dec 15.PMID: 19120346 [PubMed - indexed for MEDLINE]Related citations

    Display Settings:

    Format
    Items per page
    Sort by

    Send to:

    Choose Destination

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...
    You are here: NCBI > Literature > PubMed
    Write to the Help Desk